
Biotech article - April 21, 2025
Oncopeptides announces new RWD data
Oncopeptides has announced the publication of new real-world data (RWD) that further support the effectiveness and tolerability of melflufen, branded in Europe as Pepaxti, in patients with relapsed, refractory multiple myeloma (RRMM).

Biotech article - March 19, 2025
Scaling the next generation of T-cell therapy
Understanding the science is one thing, but being able to manufacture T-cell therapies at scale is a different matter. TCR-T cell therapies offer a path forward at a fraction of the cost and time of manufacturing a living cell as a product.

Biotech article - January 21, 2025
First Danish patients treated with gene therapy for haemophilia B
CSL Behring Denmark has announced that the first Danish patients with haemophilia B were treated with the gene therapy HEMGENIX (etranacogene dezaparvovec).

Biotech article - November 26, 2024
Anocca submits Clinical Trial Application
Anocca has announced the submission of its first Clinical Trial Application (CTA) to the European Medicines Agency (EMA) for a Phase I/II multi-asset umbrella trial, VIDAR-1.

Biotech article - November 17, 2024
#WAAW: Mini-interview SNIPR Biome
All over the Nordics the innovative power is gearing up to put new products, therapies, and preventive measures on the market that will tackle Antimicrobial resistance (AMR) from various angles.

Biotech article - November 17, 2024
#WAAW: Interview – AdjuTec Pharma
Norwegian company AdjuTec’s novel antibiotic resistance breakers may help to facilitate reduced use of antibiotics – and the company is now ready to test its product in humans.